Powered by

Tenax Therapeutics Reports Third Quarter 2020 Results and Provides Business Update

Nov 17, 2020 - Nasdaq
Financial Results

MORRISVILLE, N.C.--(BUSINESS WIRE)-- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today reported financial results for the third quarter 2020 and provided a business update.

Tenax will share updates related to levosimendan and its recently completed Phase 2 trial for the treatment of patients with pulmonary hypertension and heart failure with preserved ejection frac...